The U.S. Food and Drug Administration (or FDA) has declined to approve the psychedelic drug MDMA for the treatment of PTSD. This is marking a significant setback for advocates seeking new therapies for serious mental health issues. The drug maker announced the FDA requested an additional late-stage study, a process that typically requires years and substantial financial investment.
The request follows a previous advisory panel’s overwhelming vote against the drug’s use citing significant limitations in the submitted data that raised concerns regarding safety and efficacy. Advocates for the drug expressed disappointment, particularly for those suffering from PTSD, including veterans and abuse victims. While this decision poses challenges, experts suggest other psychedelics may stand a better chance in future FDA evaluations.
No related posts.

















